spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  NMDA 

 HSMN NewsFeed - 7 Aug 2023
NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101(TM) for Chronic Pain
Biopharmaceuticals Licensing
 HSMN NewsFeed - 5 Dec 2022
NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 26 May 2020
Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Mar 2020
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Mar 2020
Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 10 Jan 2020
Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 20 Dec 2019
Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 23 Oct 2019
NeuroRx Secures HK$ 750 Million Capital Commitment From The Gem Group for Development of NRX-101
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 Dec 2018
Mallinckrodt And NPXe Announce First Patient Enrolled In Phase 3 Trial Of Inhaled Xenon Gas Therapy
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Aug 2018
Mallinckrodt And NPXe Announce FDA Fast Track Designation For Phase 3 Trial Of Inhaled Xenon Gas Therapy
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jul 2018
Allergan Receives FDA Fast Track Designation for AGN-241751 for the Treatment of Major Depressive Disorder (MDD)
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 May 2018
Aptinyx Promotes David Houck to Chief Development Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 3 Apr 2018
Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Feb 2018
Aptinyx Appoints Ashish Khanna Chief Financial Officer and Chief Business Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 17 Jan 2018
Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 27 Dec 2017
NeuroRx Signs Agreement With U.S. Dept. of Veterans Affairs and Baylor College of Medicine for Clinical Trial of First Drug Regimen Targeting Severe Bipolar Depression in Patients With Acute Suicidal Ideation & Behavior (ASIB)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 7 Dec 2017
Aptinyx Bolsters Executive Leadership Team with Appointment of Andy Kidd as Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 2 Oct 2017
Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Sep 2017
NeuroRx Awarded FDA Fast Track Designation for First Drug Regimen Targeting Suicide in Bipolar Depression
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Jul 2017
Biohaven's BHV-5000 Receives Orphan Drug Designation from the FDA in Rett Syndrome
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 15 Jun 2017
Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 May 2017
Cerecor Appoints Steven Boyd and Peter Greenleaf to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 13 Sep 2016
Aptinyx Receives FDA Fast Track Designation for Development of NYX-2925 as Treatment for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 31 Aug 2016
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 9 Jun 2016
NUEDEXTA(R) Effective for Pseudobulbar Affect (PBA) in Patients with Alzheimer's Disease and other Dementias, Stroke and Traumatic Brain Injury
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 May 2016
Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO(TM)
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 10 May 2016
Aptinyx Raises $65 Million in Series A Financing to Advance Therapies for Neurological Disorders
Biopharmaceuticals Neurology Venture Capital Personnel
 HSMN NewsFeed - 29 Jan 2016
Allergan's Rapastinel Receives FDA Breakthrough Therapy Designation for Adjunctive Treatment of Major Depressive Disorder (MDD)
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 26 Jan 2016
Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Dec 2015
VistaGen Secures Exclusive Worldwide Commercial Rights to Three Proprietary Stem Cell Technologies from University Health Network
Biopharmaceuticals Regenerative Medicine Licensing
 HSMN NewsFeed - 11 Dec 2015
Otonomy Announces FDA Approval of OTIPRIO(TM) for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Nov 2015
Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere's Disease
Biopharmaceuticals
 HSMN NewsFeed - 5 Oct 2015
Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jul 2015
Relmada Therapeutics Appoints Charles J. Casamento to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 May 2015
Actavis Launches NAMZARIC(TM) (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer's Disease
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 24 Dec 2014
Actavis and Adamas Announce FDA Approval of Namzaric(TM), a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 3 Dec 2014
Naurex Raises $80 Million in Series C Financing to Advance Novel NMDA Receptor Modulators in Depression and Other CNS Disorders
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 Oct 2014
Otonomy Appoints Anthony J. Yost Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 May 2014
SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Mar 2014
SAGE Therapeutics Closes $38M Oversubscribed Series C Financing
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 11 Dec 2013
Relmada Therapeutics Inc. Appoints Douglas J. Beck As Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Oct 2013
SAGE Therapeutics Secures $20M Series B Financing
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 6 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 3 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 14 Aug 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 14 Aug 2013
SAGE Therapeutics Appoints Biotech Industry Veteran Dr. Jeffrey Jonas to Chief Executive Officer; Expands Leadership Team with Two Key Appointments
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 17 Dec 2012
Naurex Completes $38 Million Series B Financing
Biopharmaceuticals Neurology Venture Capital Personnel
 HSMN NewsFeed - 16 Feb 2012
Mnemosyne Pharmaceuticals, Inc. Completes $5.4 Million Series A Round to Support Drug Discovery Programs
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Nov 2011
SAGE Therapeutics Appoints Chief Scientific Officer, Strengthens Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Apr 2011
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 31 Jan 2011
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA for Pseudobulbar Affect
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Oct 2010
AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 May 2010
Adeona Completes a $17.5 Million Corporate Partnership With Meda AB for the Development and Commercialization of Flupirtine for Fibromyalgia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 Jan 2010
EpiCept Receives Orphan Drug Designation for EpiCept NP-1 in U.S.
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Aug 2009
Javelin Pharmaceuticals Reports Ereska (Intranasal Ketamine) Phase III Trial Results in Postoperative Orthopedic Pain
Biopharmaceuticals Drug Delivery Surgery
 HSMN NewsFeed - 12 May 2008
Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
Biopharmaceuticals
 HSMN NewsFeed - 11 Apr 2008
Endo Announces Executive Appointment
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Apr 2008
Status of the E2007 (perampanel) Development Program - Termination of Parkinson's Disease Clinical Development and Focus on Neuropathic Pain and Epilepsy Indications
Biopharmaceuticals
 HSMN NewsFeed - 19 Mar 2008
Forest Laboratories Announces Resignation of Ivan Gergel, MD
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Feb 2008
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Biopharmaceuticals
 HSMN NewsFeed - 1 Feb 2008
Neuro-Hitech Reports Cognitive Improvement From Phase Two Clinical Trial of Huperzine A In Alzheimer's Disease Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Jan 2008
Novexel and Forest Laboratories Announce License Agreement for NXL 104, a Novel Broad-Spectrum Beta Lactamase Inhibitor
Biopharmaceuticals Licensing
 HSMN NewsFeed - 31 Dec 2007
Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Dec 2007
Javelin Pharmaceuticals Announces Peer-Reviewed Publication of Successful Postoperative Pain Trial with PMI-100/150 (Intranasal Ketamine) in International Journal, ''Acute Pain''
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 18 Dec 2007
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 13 Dec 2007
Forest Laboratories Receives Notification of ANDA Filings for Generic Equivalents of Namenda(R)
Biopharmaceuticals Generics
 HSMN NewsFeed - 2 Dec 2007
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Nov 2007
Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
Biopharmaceuticals
 HSMN NewsFeed - 26 Nov 2007
Yaupon Therapeutics Closes $14.5 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Oct 2007
AVANIR Granted Special Protocol Assessment (SPA) From FDA for Confirmatory Phase III Trial of Zenvia in Patients With PBA
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Sep 2007
Evotec to Acquire Renovis, Seek NASDAQ Listing
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 17 Sep 2007
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Sep 2007
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 4 Sep 2007
Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 21 Aug 2007
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
Biopharmaceuticals
 HSMN NewsFeed - 8 Jun 2007
AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain
Biopharmaceuticals
 HSMN NewsFeed - 31 May 2007
Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 May 2007
BENICAR HCT(R) Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 21 May 2007
Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 1 May 2007
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 18 Apr 2007
Avanir Pharmaceuticals Announces Positive Results of Phase III Study for Zenvia in Diabetic Neuropathic Pain
Biopharmaceuticals
 HSMN NewsFeed - 14 Mar 2007
AVANIR Pharmaceuticals Appoints New Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Feb 2007
AVANIR Pharmaceuticals Summarizes Outcome of FDA Meeting on Zenvia NDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Feb 2007
Anavex Life Sciences Corp. Outlines Its Central Nervous System (CNS) Portfolio of Novel Therapeutics
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Jan 2007
Javelin Pharmaceuticals Announces Results of FDA Meeting for Nasal Ketamine
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 11 Jan 2007
Forest Laboratories Announces Completion of Acquisition of Cerexa, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Dec 2006
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Dec 2006
Forest Laboratories Announces Acquisition of Cerexa, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Oct 2006
Patient Recruitment to Resume Without Modification of Protocol for Desmoteplase Phase IIB/III Stroke Study DIAS-2
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Oct 2006
U.S. Food and Drug Administration Issues Non-Approvable Letter for Faropenem
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Sep 2006
Forest Laboratories Inc. Announces Appointment of Dr. Lawrence S. Olanoff as President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jul 2006
Forest Announces Federal Court Upholds Lexapro(R) Patent
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 23 May 2006
AVANIR Announces the Intended Acquisition of a Private Specialty Pharmaceutical Company
Biopharmaceuticals Mergers & Acquisitions
Return to NewsFeed  

 Additional items found! 55

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 55 additional stories matching:
NMDA
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.